Canaccord Genuity Group Begins Coverage on Niagen Bioscience (NASDAQ:NAGE)

Analysts at Canaccord Genuity Group began coverage on shares of Niagen Bioscience (NASDAQ:NAGE) in a research note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $13.00 price target on the stock. Canaccord Genuity Group’s price target points to a potential upside of 18.40% from the company’s previous close.

Niagen Bioscience Trading Up 3.6%

Shares of Niagen Bioscience stock opened at $10.98 on Tuesday. Niagen Bioscience has a 1 year low of $2.31 and a 1 year high of $11.06. The company has a market capitalization of $864.89 million, a price-to-earnings ratio of 64.59 and a beta of 1.94. The company’s 50 day moving average is $8.00.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.